News

The interim open label extension (OLE) analyses show that 100% of the patients who were responders for the control of plasma uric acid (PUA) in Phase III and

The preliminary analysis showed that Genz-112638 produced promising efficacy results at six months and that these results continued to improve through one year of treatment. At six months,

Under terms of the agreement Regenesis will provide its specialized sales force to market Advanced BioHealing’s product Dermagraft within the Veteran’s Administration (VA), Department of Defense (DOD), and

The data showed that Intuniv demonstrated significant efficacy in reducing attention deficit hyperactivity disorder (ADHD) symptoms for patients taking the medication when compared to patients taking placebo at

Under the terms of the agreement, Quest will receive $50,000 in cash and 1.35 million common shares of Toba Industries. In addition, Quest will also receive $200,000 in

Approval by the notified body for a CE Mark would allow CardioPass to be marketed and sold in all EU countries as well as other countries worldwide that

The randomized, parallel, double-blind, placebo-controlled, dose regimen-finding study will evaluate the safety and efficacy of two dosing regimens administered to approximately 216 patients with active, seropositive rheumatoid arthritis

Demeclocycline HCl tablets USP, in strengths of 150mg and 300mg, is an AB-Rated, therapeutically equivalent alternative to Declomycin (a trademark of Stonebridge Pharma) and is indicated in the

This analysis was conducted using data from an open-label, flexible dose, 12-month extension study in which 326 children received Daytrana. The primary objective of this study was to